272 related articles for article (PubMed ID: 25873900)
21. CX-4945 Induces Methuosis in Cholangiocarcinoma Cell Lines by a CK2-Independent Mechanism.
Lertsuwan J; Lertsuwan K; Sawasdichai A; Tasnawijitwong N; Lee KY; Kitchen P; Afford S; Gaston K; Jayaraman PS; Satayavivad J
Cancers (Basel); 2018 Aug; 10(9):. PubMed ID: 30142881
[TBL] [Abstract][Full Text] [Related]
22. Protein Kinase CK2, a Potential Therapeutic Target in Carcinoma Management.
Lian H; Su M; Zhu Y; Zhou Y; Soomro SH; Fu H
Asian Pac J Cancer Prev; 2019 Jan; 20(1):23-32. PubMed ID: 30677865
[TBL] [Abstract][Full Text] [Related]
23. Transient rRNA synthesis inhibition with CX-5461 is sufficient to elicit growth arrest and cell death in acute lymphoblastic leukemia cells.
Negi SS; Brown P
Oncotarget; 2015 Oct; 6(33):34846-58. PubMed ID: 26472108
[TBL] [Abstract][Full Text] [Related]
24. Casein Kinase 2 Inhibitor, CX-4945, as a Potential Targeted Anticancer Agent in Gastric Cancer.
Kim HM; Jeong I; Kim HJ; Kang SK; Kwon WS; Kim TS; Park KH; Jung M; Soong J; Lin SC; Chung HC; Rha SY
Anticancer Res; 2018 Nov; 38(11):6171-6180. PubMed ID: 30396934
[TBL] [Abstract][Full Text] [Related]
25. Targeting Protein Kinase CK2: Evaluating CX-4945 Potential for GL261 Glioblastoma Therapy in Immunocompetent Mice.
Ferrer-Font L; Villamañan L; Arias-Ramos N; Vilardell J; Plana M; Ruzzene M; Pinna LA; Itarte E; Arús C; Candiota AP
Pharmaceuticals (Basel); 2017 Feb; 10(1):. PubMed ID: 28208677
[TBL] [Abstract][Full Text] [Related]
26. Identification of Candidate Casein Kinase 2 Substrates in Mitosis by Quantitative Phosphoproteomics.
Rusin SF; Adamo ME; Kettenbach AN
Front Cell Dev Biol; 2017; 5():97. PubMed ID: 29214152
[TBL] [Abstract][Full Text] [Related]
27. CX-4945: the protein kinase CK2 inhibitor and anti-cancer drug shows anti-fungal activity.
Masłyk M; Janeczko M; Martyna A; Kubiński K
Mol Cell Biochem; 2017 Nov; 435(1-2):193-196. PubMed ID: 28501934
[TBL] [Abstract][Full Text] [Related]
28. Protein kinase CK2 regulates AKT, NF-κB and STAT3 activation, stem cell viability and proliferation in acute myeloid leukemia.
Quotti Tubi L; Canovas Nunes S; Brancalion A; Doriguzzi Breatta E; Manni S; Mandato E; Zaffino F; Macaccaro P; Carrino M; Gianesin K; Trentin L; Binotto G; Zambello R; Semenzato G; Gurrieri C; Piazza F
Leukemia; 2017 Feb; 31(2):292-300. PubMed ID: 27479180
[TBL] [Abstract][Full Text] [Related]
29. Targeting CK2-driven non-oncogene addiction in B-cell tumors.
Mandato E; Manni S; Zaffino F; Semenzato G; Piazza F
Oncogene; 2016 Nov; 35(47):6045-6052. PubMed ID: 27041560
[TBL] [Abstract][Full Text] [Related]
30. 4,5,7-Trisubstituted indeno[1,2-b]indole inhibits CK2 activity in tumor cells equivalent to CX-4945 and shows strong anti-migratory effects.
Birus R; El-Awaad E; Ballentin L; Alchab F; Aichele D; Ettouati L; Götz C; Le Borgne M; Jose J
FEBS Open Bio; 2022 Feb; 12(2):394-411. PubMed ID: 34873879
[TBL] [Abstract][Full Text] [Related]
31. Casein Kinase 2 Signaling in White Matter Stroke.
Nguyen H; Zhu W; Baltan S
Front Mol Biosci; 2022; 9():908521. PubMed ID: 35911974
[TBL] [Abstract][Full Text] [Related]
32. [The role of the inhibitor of apoptosis protein (IAP) family in hematological malignancies].
Grzybowska-Izydorczyk O; Smolewski P
Postepy Hig Med Dosw (Online); 2008 Feb; 62():55-63. PubMed ID: 18283236
[TBL] [Abstract][Full Text] [Related]
33. Casein Kinase 2: a novel player in glioblastoma therapy and cancer stem cells.
Agarwal M; Nitta RT; Li G
J Mol Genet Med; 2013 Dec; 8(1):. PubMed ID: 25264454
[TBL] [Abstract][Full Text] [Related]
34. Protein Kinase CK2 in Cancer Energetics.
Silva-Pavez E; Tapia JC
Front Oncol; 2020; 10():893. PubMed ID: 32626654
[TBL] [Abstract][Full Text] [Related]
35. Chemically induced degradation of CK2 by proteolysis targeting chimeras based on a ubiquitin-proteasome pathway.
Chen H; Chen F; Liu N; Wang X; Gou S
Bioorg Chem; 2018 Dec; 81():536-544. PubMed ID: 30245235
[TBL] [Abstract][Full Text] [Related]
36. Expression patterns of costimulatory molecules on cells derived from human hematological malignancies.
Zheng Z; Takahashi M; Aoki S; Toba K; Liu A; Osman Y; Takahashi H; Tsukada N; Suzuki N; Nikkuni K; Furukawa T; Koike T; Aizawa Y
J Exp Clin Cancer Res; 1998 Sep; 17(3):251-8. PubMed ID: 9894758
[TBL] [Abstract][Full Text] [Related]
37. Emodin negatively affects the phosphoinositide 3-kinase/AKT signalling pathway: a study on its mechanism of action.
Olsen BB; Bjørling-Poulsen M; Guerra B
Int J Biochem Cell Biol; 2007; 39(1):227-37. PubMed ID: 17018259
[TBL] [Abstract][Full Text] [Related]
38. Clinical-Grade Peptide-Based Inhibition of CK2 Blocks Viability and Proliferation of T-ALL Cells and Counteracts IL-7 Stimulation and Stromal Support.
Perera Y; Melão A; Ramón AC; Vázquez D; Ribeiro D; Perea SE; Barata JT
Cancers (Basel); 2020 May; 12(6):. PubMed ID: 32471246
[TBL] [Abstract][Full Text] [Related]
39. Cancer selective cell death induction by a bivalent CK2 inhibitor targeting the ATP site and the allosteric αD pocket.
Bancet A; Frem R; Jeanneret F; Mularoni A; Bazelle P; Roelants C; Delcros JG; Guichou JF; Pillet C; Coste I; Renno T; Battail C; Cochet C; Lomberget T; Filhol O; Krimm I
iScience; 2024 Feb; 27(2):108903. PubMed ID: 38318383
[TBL] [Abstract][Full Text] [Related]
40. Targeting of Protein Kinase CK2 in Acute Myeloid Leukemia Cells Using the Clinical-Grade Synthetic-Peptide CIGB-300.
Rosales M; Pérez GV; Ramón AC; Cruz Y; Rodríguez-Ulloa A; Besada V; Ramos Y; Vázquez-Blomquist D; Caballero E; Aguilar D; González LJ; Zettl K; Wiśniewski JR; Yang K; Perera Y; Perea SE
Biomedicines; 2021 Jul; 9(7):. PubMed ID: 34356831
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
